A novel method of producing the pharmaceutical intermediate (R)-2chloromandelic acid by bioconversion

2Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.
Get full text

Abstract

(R)-2-Chloromandelic acid (RCM) is one of the chiral building blocks used in the pharmaceutical industry. As a result of screening for microorganisms that asymmetrically hydrolyze racemic 2-chloromandelic acid methyl ester (CMM), Exophiala dermatitidis NBRC6857 was found to produce RCM at optical purity of 97% ee. The esterase that produces RCM, EstE, was purified from E. dermatitidis NBRC6857, and the optimal temperature and pH of EstE were 30°C and 7.0, respectively. The estE gene that encodes EstE was isolated and overexpressed in Escherichia coli JM109. The activity of recombinant E. coli JM109 cells overexpressing estE was 553 times higher than that of E. dermatitidis NBRC6857. RCM was produced at conversion rate of 49% and at optical purity of 97% ee from 10% CMM with 0.45 mg-dry-cell/L recombinant E. coli JM109 cells. Based on these findings, RCM production by bioconversion of CMM may be of interest for future industrial applications.

Cite

CITATION STYLE

APA

Yamamura, E. T., & Kita, S. (2019). A novel method of producing the pharmaceutical intermediate (R)-2chloromandelic acid by bioconversion. Bioscience, Biotechnology and Biochemistry, 83(2), 309–317. https://doi.org/10.1080/09168451.2018.1536517

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free